GlassScriptPhysician profile
Lawrence L Johnson
NPI 1114015351
$5,503.32
in general payments reported to CMS, 2019-2025
27 companies · $869 in 2025
The $869 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $231 · 2021: $609 · 2022: $1,251 · 2023: $1,000 · 2024: $1,011 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.77 |
| Education | $273.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,432.58 | 2019-2025 | |
| Janssen Biotech, INC. | $629.69 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $308.44 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $290.93 | 2022-2025 | Ilumya |
| Janssen Scientific Affairs, LLC | $222.25 | 2021-2022 | |
| Allergan, INC. | $204.29 | 2019-2022 | |
| Genzyme Corporation | $191.63 | 2019-2025 | |
| Amgen INC. | $135.37 | 2024 | Krystexxa, Otezla |
| Ucb, INC. | $125.14 | 2019-2025 | Bimzelx |
| Horizon Therapeutics Plc | $124.61 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $120.02 | 2023 | Arexvy |
| Verrica Pharmaceuticals INC. | $91.69 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.40 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $75.71 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.87 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $52.80 | 2022 | |
| Leo Pharma INC. | $52.29 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $42.78 | 2020 | |
| Incyte Corporation | $32.33 | 2022 | |
| Dermavant Sciences, INC. | $27.07 | 2023 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $24.43 | 2022 | |
| Biofrontera INC. | $19.94 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.34 | 2023 | Cyltezo |
| Galderma Laboratories, L.P. | $17.20 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $15.79 | 2024 | Valchlor |
| Vyne Pharmaceuticals INC. | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.